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I. INTRODUCTION 
The 510(k) application process for approving lower-risk medical devices 
under the Food and Drug Administration (FDA)
1
 has recently come under 
criticism for its lack of adequately measuring the safety and effectiveness of 
medical devices.
2
  To remedy this situation, the FDA created a taskforce to study 
the current 510(k) system.
3
  This taskforce recently submitted its 
recommendations to the FDA as to what changes need to be made to increase the 
effectiveness of the 510(k) application process.
4
   
The regulation of medical devices came into effect with the Medical Device 
Amendments of 1976 (MDA).
5
  These amendments were passed to encourage the 
research and development of medical devices but also “to protect the public from 
harm caused by the use of medical devices.”
6
  The MDA created the system of 
premarket approval for medical devices.
7
 It also created an exception whereby 
devices that could claim substantial equivalence to an already legally marketed 
device did not have to undergo the premarket approval process.
8
  This exception 
is currently referred to as the 510(k) approval process.   
The goal of this note is to examine how the proposed changes to the 510(k) 
system may affect future patent litigation.  This will be done by examining the 
background of the FDA approval process in detail and then exploring the changes 
that have been proposed to the 510(k) process.  Next, this article will examine 
how the 510(k) approval process affected determinations of patent validity and 
patent infringement claims in the past.  Finally, this article will analyze how the 
proposed changes to the 510(k) approval process may affect patent validity and 
patent infringement claims going forward.  
                                                        
1
 21 U.S.C. § 360e (2006).  
2
 Letter from Jeffrey Shuren, Dir., Ctr. for Devices & Radiological Health, FDA, to the 
American Public (on file with the FDA), available at 
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM239451.pd
f.   
3
 Id.   
4
 COMM. ON THE PUB. HEALTH EFFECTIVENESS OF THE FDA 510(K) CLEARANCE PROCESS, 
INST. OF MED., MEDICAL DEVICES AND THE PUBLIC’S HEALTH:  THE FDA 510(K) CLEARANCE 
PROCESS AT 35 YEARS 1 (2011) [hereinafter Committee on Effectiveness of 510(k) Process].   
5
 Medical Device Amendments of 1976, Pub. L. No. 94-295, 90 Stat. 539 (codified as amended 
at 21 U.S.C. §§ 301–392 (2006)).   
6
 William Stute, Note: Federal Preemption and the Medical Device Amendments: Medtronic, 
Inc. v. Lohr, 116 S. Ct. 2240 (1996), 23 WM. MITCHELL L. REV. 949, 956 (1997).    
7
 21 U.S.C. § 360e (2006).    
8
 See id. § 360e(b)(1)(B).   
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II. BACKGROUND TO THE FDA MEDICAL DEVICE APPROVAL PROCESS 
This section sets out how the FDA regulates medical device manufacturers, 
looking specifically at how it approves medical devices based upon their risk 
level. Medical devices are put into one of three classes based upon the level of 
risk they pose to the patient.     
A. Medical Device Regulatory Classification System 
The FDA established three different regulatory classes for medical devices
9
 
dependent upon the level of control necessary to determine their safety and 
effectiveness.
10
  Medical devices that are given a Class I status consist of low-risk 
medical devices which require only general control under the FDA.
11
  The 
standard of general control is applied to all medical devices and requires medical 
device manufacturers to follow basic regulations to ensure the safety and 
effectiveness of their medical devices.
12
  Medical devices can be given Class I 
status in two different ways.  The first is if the device is not represented for use as 
a life supporting or life-saving means, or is needed to prevent impairment of 
human health.
13
  The second is if the device “does not present a potential 
unreasonable risk of illness or injury.”
14
   
Medical devices that are given Class II status are moderate-risk devices that 
require both general controls and special controls.
15
  Special controls are supposed 
to provide assurance of the safety and effectiveness of the device.
16
  Special 
controls for Class II status medical devices include “promulgation of performance 
standards, postmarket surveillance, patient registries, development and 
dissemination of guidelines . . . recommendations, and other appropriate actions 
as the Secretary deems necessary . . . .”
17
 
                                                        
9
 21 U.S.C. § 360c (2006).                                                                        
10
 U.S. Food and Drug Admin., Device Classification,  
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYourDevic
e/default.htm [hereinafter Device Classification] (last updated Apr. 27, 2009).   
11
 See 21 U.S.C. § 360c(a)(1)(A) (2006).     
12
 See id. § 360c(a)(1)(A)(i); U.S. Food and Drug Admin., General Controls for Medical 
Devices, 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecial
Controls/ucm055910.htm (last updated May 13, 2009).  
13
 21 U.S.C. § 360c(a)(1)(A)(ii)(I) (2006).   
14
 Id. § 360c(a)(1)(A)(ii)(II).   
15
 Id. § 360c(a)(1)(B).   
16
 Id.; see also U.S. Food and Drug Admin., General and Special Controls, 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecial
Controls/default.htm (last updated Apr. 23, 2009). 
17
 21 U.S.C. § 360c(a)(1)(B) (2006).   
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Medical devices that are given Class III status are high-risk medical devices 
that require both general controls and premarket approval.
18
  Premarket approval 
is a complex and comprehensive system for proving the safety and effectiveness 
of devices that are purported for use in supporting or sustaining human life, or 
devices that may present unreasonable risks of illness or injury.
19
  The 
requirements for obtaining premarket approval are set forth in 21 U.S.C. § 360e.
20
   
As such, the regulatory class is generally dispositive of the manner in which 
the FDA approves a medical device for marketing.
21
  Class I and Class II medical 
devices may be exempt from any approval process if they are either pre-
amendment devices that have not been significantly changed or modified, or if 
they are specifically exempt by regulation.
22
  Otherwise, Class I and Class II 
medical devices must be approved for market by the FDA through the submission 
of a 510(k) application.
23
  Class III medical devices must be approved under a 
Premarket Approval application, unless the device is a preamendment device and 
premarket approval has not been called for.
24
   
B. Background of the 510(k) Process 
The 510(k) process of approving a medical device is a quicker and less 
demanding way to bring a device to market as compared to the premarket 
approval process.  The main goals of the 510(k) program are to facilitate 
innovation by allowing medical devices to come to market faster, while ensuring 
that all medical devices are safe and effective.
25
  The 510(k) program requires that 
                                                        
18




 (2006); see also U.S. Food and Drug Admin., Premarket Approval (PMA), 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/Pr
emarketSubmissions/PremarketApprovalPMA/default.htm [hereinafter Premarket Approval] (last 
updated Jan. 24, 2012).  
21
 See Premarket Approval, supra note 20.    
22
 U.S. Food and Drug Admin., Class I/II Exemptions, 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYourDevic
e/ucm051549.htm (last updated May 13, 2009).  Preamendment devices refer to devices that had 
been marketed in the U.S. prior to the Medical Device Amendments of 1976.  Id.  The Medical 
Device Amendments were intended to give the FDA authority over the approval of medical 
devices depending on their safety and effectiveness.  See Medical Device Amendments of 1976, 
supra note 5. 
23
 21 U.S.C. § 360e (2006); see also Device Classification, supra note 10.    
24
 Device Classification, supra note 10.   
25
 U.S. Food and Drug Admin., 510(k) and Science Report Recommendations: Summary and 
Overview of Comments and Next Steps, 1 (2011) [hereinafter 510(k) and Science Report 
Recommendations], 
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM239449.pd
f (last visited Apr. 18, 2012).   
5
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all Class I and Class II medical device manufacturers (except those that are 
exempt) submit their 510(k) application ninety days before they plan on bringing 
their product to market.
26
   
Under the current regulations, a 510(k) submission should include basic 
information about the device including the name of the device, what class the 
device falls within, and information about the company marketing the device.
27
  A 
submission must include information that will be used to market the device, 
including proposed labeling and advertising materials.
28
  Title 21 of the Code of 
Federal Regulations states in section 807.87(e) that “[w]here applicable, 
photographs or engineering drawings should be supplied.”
29
  One must also 
include a brief description of the device, including an explanation of how the 
device functions, the scientific concepts that form the basis for the device, and the 
significant physical and performance characteristics of the device which may 
include what materials are used to manufacture the device, the physical properties 
of the device, and the design of the device.
30
   
One must also include a statement of substantial equivalence to a predicate 
device in the form of “a statement indicating the device is similar to and/or 
different from other products of comparable type in commercial distribution, 
accompanied by data to support the statement.”
31
  This means direct comparison 
of the proposed medical device to the “predicate [device]”, to which the 510(k) 
submission is claiming equivalence.
32
  
C. Confidentiality of the 510(k) Application 
The FDA lists the name, manufacturer, and the 510(k) summary of all 
approved 510(k) applications on their website within a month of their approval.
33
  
                                                        
26
 21 C.F.R. § 807.81 (2012).   
27
 21 C.F.R. § 807.87(a)–(d) (2012); see also U.S. Food and Drug Admin., Content of a 510(k), 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/Pr
emarketSubmissions/PremarketNotification510k/ucm142651.htm [hereinafter Content of a 
510(k)] (last updated Mar. 15, 2012) (listing other elements required to ensure that the 510(k) is 
complete).   
28
 21 C.F.R. § 807.87(e) (2012).   
29
 Id.   
30
 Id. § 807.92(a)(4).   
31
 Id. § 807.87(f).   
32
 Id. § 807.92(a)(3).   
33
 U.S. Food and Drug Admin., 510(k) Clearances, 
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearan
ces/510kClearances/default.htm [hereinafter 510(k) Clearances] (last visited Mar. 24, 2012); see, 
e.g., U.S. Food and Drug Admin., January 2011 510(k) Clearances, 
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearan
ces/510kClearances/ucm242640.htm (last updated Apr. 21, 2011).   
6
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Typically, all medical devices that are approved are listed on the FDA’s website 
unless the 510(k) application can be deemed confidential.
34
  A medical device 
510(k) application can be deemed confidential if the device is not on the market 
and it has been made clear that the manufacturer does not intend to market the 
device within ninety days of the 510(k) submission.
35
  To ensure confidentiality 
one must request that the 510(k) application be kept confidential by stating that no 
notification has been made to anyone about the intent to someday market the 
device, and the commissioner must agree that the intent to market the device 
should be kept as confidential commercial information.
36
 
III. PROPOSED CHANGES TO THE 510(K) PROCESS 
The 510(k) process has come under criticism lately for not being a sound 
system to approve devices for market.
37
  The 510(k) system works by evaluating a 
medical device’s safety and effectiveness by comparing the new medical device 
to another medical device that is considered a substantial equivalent of the new 
medical device.
38
  Thus, a medical device may be approved under the 510(k) 
system if it could be deemed substantially equivalent to another medical device 
that was also approved under the 510(k) system, ad infinitum.  This leads to a 
situation where a medical device that is approved through a 510(k) application 
may be based upon a substantially equivalent medical device that was on the 
market prior to 1976, and as such has never been approved by the FDA.
39
   
In August 2010, the FDA’s Center for Devices and Radiological Health 
(CDRH) released the preliminary reports from their 510(k) Working Group that 
was established to review the 510(k) process and propose changes to the 
program.
40
  The FDA also asked the Institute of Medicine (IOM) to create a task 
force to review the 510(k) system as an outside party.  The IOM created the 
Committee on the Public-Health Effectiveness of the FDA 510(k) Clearance 
Process and released their recommendations to the FDA in July 2011.
41
   
                                                        
34
 See 510(k) Clearances, supra note 33. 
35
 21 C.F.R. § 807.95(b) (2012).   
36
 Id. §§ 807.95(b)(1)-(2).   
37
 See, e.g., Letter from Jeffrey Shuren, supra note 2, at 1.   
38
 See 21 C.F.R. §§ 807.87(j) (2012); see also Content of a 510(k), supra note 27.   
39
 David R. Challoner & William W. Vodra, Medical Devices and Health — Creating a New 
Regulatory Framework for Moderate-Risk Devices, 365 NEW ENG. J. MED. 977, 978 (2011), 
available at http://www.nejm.org/doi/full/10.1056/NEJMp1109150.  
40
 510(k) and Science Report Recommendations, supra note 25, at 1.     
41
 Committee on Effectiveness of 510(k) Process, supra note 4, at 3. 
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A. The Institute of Medicine’s Recommendations 
In a letter from David Challoner
42
 to Jeffrey Shuren
43
 sent July 20, 2011, the 
IOM stated it was their opinion that the 510(k) process “generally is not intended 
to evaluate the safety and effectiveness of medical devices and, furthermore, 
cannot be transformed into a premarket evaluation of safety and effectiveness.”
44
  
Thus, IOM’s recommendations focused not on what changes should be made to 
the 510(k) system but rather on what changes need to be made overall to develop 
a more rational regulatory framework for medical devices.
45
   
The IOM’s report concluded that the 510(k) process lacks the legal basis to be 
a reliable premarket screen of the safety and effectiveness of moderate-risk 
devices.
46
  The IOM also focused on the fact that the postmarket surveillance 
which should be required for medical devices is basically nonexistent under the 
current 510(k) system.
47
  The IOM suggested that the FDA work to develop a new 
framework for an integrated pre-market and post-market regulatory system that 
would focus more intently on the safety and effectiveness of each device 
throughout its life cycle.
48
  The IOM suggested that the new regulatory system 
utilize the following six criteria:   
[B]e based on sound science; be clear, predictable, straightforward, 
and fair; be self-sustaining and self-improving; facilitate 
innovation that improves public health by making medical devices 
available in a timely manner and ensuring their safety and 
effectiveness throughout their lifecycle; use relevant and 
appropriate regulatory authorities and standards throughout the life 




B. Overview of FDA’s Proposed Changes 
In the preliminary reports released in August 2010, the FDA’s Task Force and 
Working Group suggested fifty-five changes to improve the 510(k) program and 
                                                        
42
 Chair for the Committee on the Public-Health Effectiveness of the FDA 510(k) Clearance 
Process 
43
 Director of Center for Devices & Radiological Health 
44
 Letter from David Challoner, Chair, Comm. on the Public-Health Effectiveness of the FDA 
510(k) Clearance Process, Inst. of Med., to Jeffrey Shuren, Dir., Ctr. for Devices & Radiological 
Health, Food and Drug Admin. (July 20, 2011) (on file with IOM).   
45
 Id. at 2.   
46
 Committee on Effectiveness of 510(k) Process, supra note 4, at 3. 
47
 Id.   
48
 Id.   
49
 Id.    
8
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  The FDA stated in its report, 510(k) and Science Report 
Recommendations, that it planned to implement a portion of the report’s 
recommendations in 2011 by taking twenty-five actions which it laid out in its 
Plan of Action included in the report.
51
  The recommendations that will be 
implemented first will be those that foster innovation, enhance regulatory 
predictability, and improve patient safety.
52
  The changes that will be 
implemented include issuing guidance to provide greater clarity about the 510(k) 
program and improving training for CDRH staff and industry.
53
  In January 2012, 
the FDA published a list of the accomplishments they had made under their 
510(k) Plan of Action.
54
  The changes that the FDA plans to make that may affect 
the area of patent law are further discussed below.   
1. Adoption of the Use of an “Assurance Case” Framework for 510(k) 
Submissions 
An assurance case is a formal method to prove the validity of a particular 
claim by a party submitting a convincing argument along with supporting 
evidence.
55
  Implementing an assurance case framework for 510(k) applications 
would mean that all information that is submitted to the FDA concerning the 
description of the device and the intended use of the product would need to be 
submitted in a more detailed section of the 510(k) application.
56
  Using an 
assurance case framework would mean that each 510(k) submission would be 
held to a higher level of completeness and it may prevent early submissions that 
take too long to correct, thus burdening the FDA review process.  To begin to 
implement this suggestion, the FDA began a pilot program to study the use of an 
assurance framework for infusion pumps
57
 to determine whether an assurance 
case framework should be broadly applied.
58
   
                                                        
50
 510(k) and Science Report Recommendations, supra note 25, at 3.   
51
 Id.   
52
 Id. at 2. 
53
 Id.   
54
 U.S. Food and Drug Admin., CDRH Plan of Action for 510(k) and Science, 1 (2012) 
[hereinafter CDRH Plan of Action for 510(k) and Science], 
http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/
CDRH/CDRHReports/UCM276316.pdf.   
55
 510(k) and Science Report Recommendations, supra note 25, at 16.   
56
 Id.  
57
 An infusion pump is a Class II medical device intended for use in a health care facility to 
pump fluids into a patient in a controlled manner.  21 C.F.R. § 880.5725 (2012).   
58
 CDRH Plan of Action for 510(k) and Science, supra note 54, at 1.  
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2. Submit All Scientific Information Regarding Safety and/or Effectiveness 
The 510(k) Working Group also recommended changing the statutory test of 
21 C.F.R. § 807.87 to explicitly require anyone submitting a 510(k) application to 
submit a list and brief description of all scientific information that is known or 
should be known regarding the safety and/or effectiveness of a new device.
59
  
Because this recommendation may become burdensome (especially if the 
information is not known but would need to be discovered because it should be 
known), the FDA decided to implement this recommendation on a case-by-case 
basis.
60
  Thus, the FDA has decided to create device-specific guidance to instruct 
510(k) submitters as to when they should submit information about the safety and 
effectiveness of a new device.  Further, they will initially only require 510(k) 
submitters to submit information that is already known.
61
 
3. Submission of Photographs and Schematics 
Under the current 510(k) system, photographs and schematics are sometimes 
submitted with a 510(k) application; the FDA has found this information to be 
helpful in making a determination of substantial equivalence.
62
  The FDA 
therefore decided to change the system to require the submission of detailed 
photographs and schematics in order to help improve reviewer efficiency and 
effectiveness.
63
  To effectively implement this change, the FDA held a public 
meeting on April 7, 2011 to get public feedback on the change.
64
  The results of 
this public meeting were not available at the time this article was completed.   
4. Submission of Manufacturing Process Information 
The CDRH already has the ability to request manufacturing information for 
some devices, but there has been no clarity given about when the ability will be 
used or should be used.
65
  The change recommended by the CDRH is to provide 
greater clarity about when this right will be or should be exercised.
66
  The CDRH 
plans on implementing this recommendation by providing guidance on when the 
manufacturing information will be requested and pointing to the fact that they will 
be interested in getting manufacturing information for higher-risk devices.
67
  This 
                                                        
59
 510(k) and Science Report Recommendations, supra note 25, at 17.   
60
 Id.     
61
 Id.     
62
 Id. at 8.   
63
 Id. at 8–9.   
64
 CDRH Plan of Action for 510(k) and Science, supra note 54, at 1. 
65
 510(k) and Science Report Recommendations, supra note 25, at 19.   
66
 Id.   
67
 Id.    
10
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recommendation will be initially implemented on a case-by-case basis for higher-
risk devices and will be tailored to address relevant issues specific to that type of 
device.
68
   
5. Use of “Multiple Predicates”  
Under the current 510(k) program, a manufacturer of a medical device can use 
a “multiple predicate” or “split predicates” when claiming that its device is 
substantially equivalent to an existing device.
69
  This means that a comparison can 
be made to one existing device to show the same “intended use” while a 
comparison can be made to a different existing device to show the new device’s 
“technological characteristics”.
70
  The 510(k) Working Group recommended that 
the CDRH develop guidance on the appropriate use of more than one predicate, 
while at the same time exploring the possibility of explicitly disallowing the use 
of “split predicates.”
71
  This change would mean that in order to submit a 510(k) 
application that would be approved, a medical device manufacturer would have to 
use the same predicate device and claim that their device is substantially 
equivalent to the predicate device in terms of both intended use and technological 
characteristics.  At the time of this writing, the CDRH had completed a 
preliminary study to review how safe and effective medical devices are when they 
claim more than one predicate device.
72
  The CDRH’s current plan of action is to 
implement guidance to clarify when it is appropriate to use multiple predicates, 
while continuing to monitor what effect these changes might make.
73
   
6. A New Subset of Class IIb Devices 
One major change the FDA recommended is the creation of a new subset of 
medical devices called Class IIb.
74
  The Class IIb devices would potentially 
require that clinical information, information about manufacturing processes, and 
additional evaluation in the postmarket setting be required under the 510(k) 
program for a particular subset of higher risk Class II devices.
75
  The FDA 
explains that they are not proposing a brand new class of devices.  Rather they 
would try to group higher-risk Class II devices under a “Class IIb” setting when 
                                                        
68
 Id. at 19–20.   
69
 Id. at 14.  
70
 Id.   
71
 Id.   
72
 U.S. Food and Drug Admin., Medical Device Reporting (MDR) Rate in 510(k) Cleared 
Devices Using Multiple Predicates,  
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CD
RHReports/ucm275629.htm (last updated Nov. 12, 2011).  
73
 510(k) and Science Report Recommendations, supra note 25, at 14.   
74
 Id. at 17.   
75
 Id.   
11
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filing a 510(k) application so that those device manufacturers are aware that more 
information would likely be requested by the FDA before their 510(k) application 
would be approved under the new guidelines.
76
  The FDA further explained that 
there would be no clear-cut delineation between what qualified as a Class IIa or 
Class IIb device.
77
  Rather the classification would be determined based upon 
prior approved devices, and new devices would not be classified into Class IIa or 
IIb until the FDA had time to meet with and talk to the submitters.
78
  The FDA 
had not provided a timeline for implementing this recommendation at the time of 
this writing.
79
   
7. Publicly Available 510(k) Searchable Database 
The 510(k) Working Group recommended that the CDRH develop a 
searchable database for all verified 510(k) applications.
80
  It recommended that 
this database include the 510(k) summary, photographs and schematics of the 
device (to the extent that they do not contain proprietary information), and 
information showing how the current 510(k) application is similar to its claimed 
predicate device(s).
81
  Industry participants raised concerns about having detailed 
schematics, drawings, and/or photographs available to the public because of the 
increased potential for patent infringement and reverse engineering.
82
  The FDA 
has explained that the ‘photographs or schematics’ referred to by the Working 
Group is actually only one photograph or one schematic given by the 510(k) 
submitter to be used in the database, thus not giving away proprietary 
information.
83
  Due to this concern, the FDA held a public meeting on April 7, 
2011 to receive public comments about this recommendation.
84
  At the time of 
this writing, the FDA had not publically announced how it planned to proceed in 
regards to photographs and schematics going forward.   
                                                        
76
 Id. at 18.   
77
 Id.     
78
 Id.   
79
 See id. at 19.   
80
 Id. at 20.    
81
 Id.   
82
 Id. at 21.   
83
 Id. at 21.   
84
 U.S. Food and Drug Admin., 510(k) Implementation: Discussion of an On-line Repository of 
Medical Device Labeling, and of Making Device Photographs Available in a Public Database 
Without Disclosing Proprietary Information, April 7, 2011, 
http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm243829.htm (last 
updated May 13, 2011).   
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IV. ISSUES WITH PATENT VALIDITY 
The following section analyzes how the 510(k) application may play into the 
validity of patents.  As will be explained below, some courts have considered the 
510(k) application materials when determining patent validity and some courts 
have decided that 510(k) materials should not be allowed to play into the 
determination.  There is currently no binding rule about how 510(k) application 
materials can or should play into determining the validity of a patent during 
litigation.   
A. Elements to Consider When Determining the Validity of a New Patent 
There are four different criteria that patent applications have to fulfill before 
the patent application will be granted: that the invention be a new process, 
machine, manufacture, or composition of matter;
85
 that the invention be useful;
86
 
that the invention be novel;
87
 and that the invention be non-obvious.
88
  The 
following sections evaluate how the 510(k) application may play into the 
requirements of patentability and the filing of the patent application.   
1. Novelty 
Section 102 of the Patent Act sets out the conditions for patentability.
89
  
Section 102 reads in part: 
A person shall be entitled to a patent unless- (a) the invention was 
known or used by others in this country, or patented or described 
in a printed publication in this or a foreign country, before the 
invention thereof by the applicant for patent, or (b) the invention 
was patented or described in a printed publication in this or a 
foreign country or in public use or on sale in this country, more 
than one year prior to the date of the application for patent in the 




This section sets out the concept of novelty in terms of anticipation.  “[I]f a device 
or process has been previously invented (and disclosed to the public), then it is 
                                                        
85
 35 U.S.C. § 101 (2006).   
86
 Id.   
87
 Id. § 102.   
88
 Id. § 103.   
89
 Id. § 102.   
90
 Id. § 102(a)–(b).  
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In Johnson & Johnson Vision Care, Inc. v. CIBA Vision Corp., the plaintiffs 
argued that the defendants patent was not valid because it was “anticipated.”
92
  
This argument was founded in part on the fact that the defendant had filed a 
510(k) application with the FDA for the approval of their medical device one year 
before they filed their patent.
93
  The defendant argued that while they filed their 
510(k) application over a year before they filed their patent application, the 
510(k) application was not made “public” as required by § 102 because the 510(k) 
application was not made public until they were within a year of filing their patent 
application.
94
  The court held that while it was known that a 510(k) application 
had been filed, it cannot, by clear and convincing evidence, show that the medical 
device was known such as to anticipate the patent.
95
 
In Arthrocare Corp. v. Smith & Nephew, Inc., the defendant tried to argue that 
the 510(k) application materials that had been submitted to the FDA should have 
been admitted into evidence as relevant to the issue of anticipation.
96
  Particularly 
the defendant “charge[d] that the submissions demonstrate that the commercial 
embodiments of the patents in suit have the same principles of operation as prior 
art devices.”
97
  The court ruled that the 510(k) application materials were not 
admissible as evidence, because the 510(k) submissions claimed equivalence to 
commercial embodiments and not the particular claims of the asserted prior art.
98
   
In Mentor H/S, Inc. v. Medical Device Alliance, Inc., the jury considered the 
510(k) applications in their decision that every element for finding anticipation 
was fulfilled.
99
  The district court overruled the jury’s decision and found that the 
elements for anticipation were not found, but was subsequently overruled by the 
Federal Circuit.
100
  The Federal Circuit rested their decision on the fact that the 
jury’s decision was not against the great weight of the evidence.
101
   
                                                        
91
 Net MoneyIN, Inc. v. VeriSign, Inc., 545 F.3d 1359, 1369 (Fed. Cir. 2008).   
92
 Johnson & Johnson Vision Care, Inc. v. CIBA Vision Corp., 634 F. Supp. 2d 1293, 1308 (D. 
Fla. 2008).   
93
 Id.   
94
 Id.   
95
 Id. at 1310.   
96
 Arthrocare Corp. v. Smith & Nephew, Inc., 310 F. Supp. 2d 638, 667 (D. Del. 2004).   
97
 Id.     
98
 Id.     
99
 Mentor H/S, Inc. v. Med. Device Alliance, Inc., 244 F.3d 1365, 1372 (Fed. Cir. 2001).   
100
 Id. at 1380.     
101
 Id. at 1376.      
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As seen from the previous decisions, the issue of whether 510(k) applications 
materials should play into the finding of novelty for patent applications is not 
resolved.
102
  Some courts have allowed the 510(k) application to go to the jury as 
evidence,
103
 while other courts are less certain about whether or not the 510(k) 
application contains relevant information for finding anticipation under § 102.
104
 
2. Obviousness  
Section 103 of the Patent Act sets out the criteria of non-obviousness for 
patent applications.
105
  Section 103 reads in part as: 
A patent may not be obtained though the invention is not 
identically disclosed or described as set forth in section 102 of this 
title, if the differences between the subject matter sought to be 
patented and the prior art are such that the subject matter as a 
whole would have been obvious at the time the invention was 
made to a person having ordinary skill in the art to which said 
subject matter pertains.  Patentability shall not be negatived by the 
manner in which the invention was made.
106
   
As set out in Perfect Web Technologies, Inc. v. InfoUSA, Inc., a determination of 
obviousness requires consideration of the “(1) the scope and content of the prior 
art, (2) the differences between the prior art and the claims at issue, (3) the level 
of ordinary skill in the pertinent art, and (4) secondary considerations of 
nonobviousness.”
107
   
 In Johnson & Johnson Vision Care, the plaintiff also claimed that the 
defendant’s patent application was obvious due to the submission of the 510(k) 
application.
108
  It argued that the predicate devices listed in the 510(k) application 
and the prior art listed on the patent application disclosed the technology in the 
patent application and thus deemed the patent obvious.
109
  The court denied the 
                                                        
102
 See supra notes 91, 92, 96, 99 and accompanying text.   
103
 See Mentor H/S, Inc., 244 F.3d 1365.   
104
 See Johnson & Johnson Vision Care, Inc. v. CIBA Vision Corp., 634 F. Supp. 2d 1293 (D. 
Fla. 2008); Arthrocare Corp. v. Smith & Nephew, Inc., 310 F. Supp. 2d 638 (D. Del. 2004).   
105
 35 U.S.C. § 103 (2006).   
106
 Id. § 103(a).   
107
 Perfect Web Techs., Inc. v. InfoUSA, Inc., 587 F.3d 1324, 1327 (Fed. Cir. 2009) (citing 
KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 406 (2007)). 
108
 Johnson & Johnson Vision Care, Inc., 634 F. Supp. 2d at 1307.   
109
 Id. at 1317.     
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defendant’s motion for summary judgment but never explicitly stated if its 
decision rested upon the use of the 510(k) application materials.
110
 
B. Inequitable Conduct Before the United States Patent and Trademark 
Office 
The other issue to consider when evaluating the validity of a patent is how the 
applicant conducts itself before the United States Patent and Trademark Office 
(USPTO).  In Mentor H/S, Inc., the district court concluded that the: 
[J]ury’s verdict was against the great weight of the evidence 
because [the defendant] asserted in his 510(k) application to the 
FDA that his prototype was similar in design to the [substantially 
equivalent device], but then failed to disclose his opinion regarding 
the similarity of the products to the PTO during prosecution of the 
. . . patent.
111
 
The Federal Circuit reversed the district court’s decision on inequitable conduct 
after finding that the jury’s decision was not against the great weight of the 
evidence, thus finding that the defendant had not represented himself in an 
inequitable manner before the USPTO.
112
   
As evidenced in the jury’s decision in Mentor H/S, Inc. and by the panel of 
Federal Circuit judge’s decision that the district court erred in ruling contrary to 
the jury’s findings, the 510(k) application materials were used as evidence to 
determine whether inequitable conduct before the USPTO had taken place.
113
  
Thus, it appears as if the 510(k) application materials may sometimes be used in 
considerations of inequitable conduct and that the 510(k) materials may be 
submitted as evidence to the jury.   
V. INTERSECTION WITH PATENT LITIGATION 
The following sections examine how the use of 510(k) application materials, 
particularly the substantial equivalence claim that is made on 510(k) applications, 
intersects with patent litigation.   It has been decided by the Supreme Court that 
the substantial equivalence claim made on 510(k) application materials is not an 
admission of infringement.  But there is currently no binding rule as to how 
510(k) application materials may play into other considerations during patent 
infringement litigation.   
                                                        
110
 Id. at 1319 (holding that “there is sufficient evidence to create a triable issue of fact on the 
issue of obviousness”).     
111
 Mentor H/S, Inc. v. Med. Device Alliance, Inc., 244 F.3d 1365, 1372 (Fed. Cir. 2001).   
112
 Id. at 1378.     
113
 Id. at 1365.     
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A. Eli Lilly and Co. v. Medtronic, Inc. 
Eli Lilly was decided by the Supreme Court in 1990 and analyzed the 
intersection between patent infringement and the materials that are submitted to 
the FDA for medical device approval.
114
  The Court held that the alleged 
infringer’s use of a patented invention to develop and submit information for 
marketing approval of medical devices under the Federal Food, Drug and 
Cosmetic Act was not infringement.
115
  This decision was based on section 271(e) 
of the Patent Act.  Section 271(e) of the Patent Act states that: 
It shall not be an act of infringement to make, use, offer to sell, or 
sell within the United States or import into the United States a 
patented invention . . . solely for uses reasonably related to the 
development and submission of information under a Federal law 




The parties to this suit argued whether the text, which appears to apply to 
pharmaceutical drugs, was intended by Congress to apply to medical devices.
117
  




Since this decision it has come to be widely held that substantial equivalent 
claims that are made in 510(k) applications cannot be construed as admissions of 
direct infringement.
119
  This may have lead to the general idea that 510(k) 
application materials are not admissible as evidence at trial, but recent court cases 
may cause some to hesitate.
120
  While courts still hold that the prior art used on 
FDA 510(k) applications are not an admission of direct infringement,
121
 there 
have been some recent decisions that allow the use of 510(k) materials to be 
considered in patent litigation cases as supporting materials to other claims.
122
   
                                                        
114
 Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990).   
115
 Id. at 668–69.     
116
 35 U.S.C. § 271(e)(1) (2006).   
117
 Eli Lilly & Co., 496 U.S. at 665.   
118
 Id. at 679.     
119
 See, e.g., Am. Med. Sys., Inc. v. Laser Peripherals, LLC, 712 F. Supp. 2d 885, 905 (D. 
Minn. 2010); Sunrise Med. HHG, Inc. v. Airsep Corp., 95 F. Supp. 2d 348, 406 (W.D. Pa. 2000).   
120
 See, e.g., U.S. Surgical Corp. v. Hospital Prods. Int’l Pty., Ltd, 701 F. Supp. 314 (D. Conn. 
1988) (allowing the admission of 510(k) materials as evidence for deciding whether infringement 
has happened.).   
121
 See Eli Lilly & Co., 496 U.S. 661.   
122
 See, e.g., U.S. Surgical Corp., 701 F. Supp. 314.   
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B. Patent Infringement 
Since Eli Lilly, courts have repeatedly held that the 510(k) application is not 
an admission of patent infringement,
123
 but they have considered allowing the 
510(k) to be admitted at trial as evidence in patent infringement cases.
124
  This 
section reviews some of the concerns that arise when considering the intersection 
between the FDA’s 510(k) process and patent litigation, especially in light of the 
recently proposed changes to the FDA 510(k) process.   
1. Direct Infringement  
Direct infringement of a patent occurs when “whoever without authority 
makes, uses, offers to sell, or sells any patented invention, within the United 
States or imports into the United States any patented invention during the term of 
the patent . . . .”
125
  Courts have typically applied a two-part test to determine 
whether direct infringement has occurred.
126
  The first step, commonly known as 
claim construction, is to define the meaning and scope of the patent claims alleged 
to be infringed.
127
  The second step is to compare those claims to the alleged 
infringing device.
128
   
In United States Surgical Corp. (USSC) v. Hospital Products International 
Pty. Ltd, the plaintiff was bringing an action for infringement of its surgical 
stapling device against the defendant.
129
  The court stated that:  
[T]he defendants have gone so far as to cause statements to be 
made that may be construed as admissions of infringement.  For 
example, on October 28, 1980, HPI submitted to the United States 
Food and Drug Administration a § 510(k) pre-market notification . 
. . [that] stated in the notification that these devices were 
equivalent to their USSC counterparts. . . . Similarly, on November 
16, 1981, SCI submitted to the FDA a second § 510(k) pre-market 
notification to announce its intention to sell its ILA anastomosis 
                                                        
123
 See, e.g., Am. Med. Sys., Inc., 712 F. Supp. 2d at 905 (citing CardioVention, Inc. v. 
Medtronic, Inc., 483 F. Supp. 2d 830, 840 (D. Minn. 2007)).   
124
 See, e.g., U.S. Surgical Corp., 701 F. Supp. at 347. 
125
 35 U.S.C. § 271(a) (2006).   
126
 Markman v. Westview Instruments, Inc., 52 F.3d 967, 976 (Fed. Cir. 1995), aff’d, 517 U.S. 
370 (1996).   
127
 Id. (citing Read Corp. v. Portec, Inc., 970 F.2d 816, 821 (Fed. Cir. 1992) (abrogated on 
other grounds)). 
128
 Id. at 976.  Direct infringement occurs where each limitation of at least one claim of the 
patent is found exactly in the alleged infringer’s product.  See, e.g., Johnston v. IVAC Corp., 885 
F.2d 1574, 1577 (Fed. Cir. 1989); Panduit Corp. v. Dennison Mfg. Co., 836 F.2d 1329, 1330 n.1 
(Fed. Cir. 1987).   
129
 U.S. Surgical Corp., 701 F. Supp. at 317.   
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surgical stapling equipment.  The SCI device was stated to be 
“substantially equivalent” to USSC’s GIA surgical stapler . . . .
130
   
The court ultimately held that HPI did in fact infringe upon USSC’s surgical 
stapling device patents.
131
  This decision did not rely solely on the information 
provided in the 510(k) application, but the court did consider the information 
provided in the 510(k) application and allowed it to be admissible as evidence for 
the plaintiff to prove that infringement had taken place.
132
   
In contrast, the 510(k) application materials were not allowed in court to 
prove direct infringement in American Medical Systems, Inc. v. Laser 
Peripherals, LLC.
133
  In American Medical Systems, the plaintiff relied on the 
defendant’s representation made to the FDA in the form of the 510(k) that 
claimed its product was substantially equivalent to the plaintiff’s invention.  The 
court, following the majority trend, decided this was not an admission of 
infringement, because substantial equivalence means something different in the 
FDA context than it does in the patent infringement context.
134
  It appears as if the 
court choose not to decide whether the 510(k) application should be admissible as 
evidence on its face, but rather decided that the information would be confusing to 
a jury and may distract from the litigation at hand.   
A similar justification was used for not considering the 510(k) application 
material in Sunrise Medical HHG, Inc. v. Airsep Corp.
135
  The court stated that 
they placed no reliance on the 510(k) application as “[i]ts sole purpose was to 
demonstrate to the FDA that the [infringing product] was as safe and effective as 
the [patented invention].  That purpose was accomplished without any discussion 
of the differences between the two devices . . . .”
136
 
Courts have tended to rule that the 510(k) application materials are not 
admissible as admissions of infringement, but they have yet to determine whether 
the 510(k) application materials should be considered when looking at a claim for 
                                                        
130
 Id. at 347. 
131
 Id. at 352–53.  The court found that the defendant failed to prove the plaintiff’s patents were 
invalid or unenforceable and that the plaintiff had proven its claim for infringement.  Id. 
132
 Id. at 347.   
133
 712 F. Supp. 2d 885, 905 (D. Minn. 2010).   
134
 Id. at 905.  The court here relied on the ruling in CardioVention, Inc. v. Medtronic, Inc., 483 
F. Supp. 2d 830 (D. Minn. 2007), where the court decided in a case of patent validity that the 
510(k) information was not admissible to show invalidity of a patent because admission of the 
510(k) application materials would be misleading and unfairly prejudicial.  CardioVention, Inc., 
483 F. Supp. 2d at 840. 
135
 Sunrise Med. HHG, Inc. v. Airsep Corp., 95 F. Supp. 2d 348, 406 (W.D. Pa. 2000).   
136
 Id. at 406.  The court does not cite any other opinions regarding whether or not to consider 
510(k) application materials in patent litigation. Id. 
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direct infringement.  For example, the court in United States Surgical 
Corporation decided to take the 510(k) application materials into account when 
deciding whether direct infringement has happened,
137
 while the courts in 
American Medical Systems, Inc., and Sunrise Medical HHG, Inc. decided not to 
consider the 510(k) application materials because they did not find them 
applicable to a finding of direct infringement.
138
  Without a precedential decision 
of whether the 510(k) application materials should be admissible as evidence to 
support a finding of direct infringement, companies should be careful about the 
information that is included in their 510(k) applications.   
2. Contributory Infringement 
Contributory infringement is set out in the Patent Act in § 271(c):   
Whoever offers to sell or sells within the United States or imports 
into the United States a component of a patented machine, 
manufacture, combination or composition, or a material or 
apparatus for use in practicing a patented process, constituting a 
material part of the invention, knowing the same to be especially 
made or especially adapted for use in an infringement of such 
patent, and not a staple article or commodity of commerce suitable 
for substantial noninfringing use, shall be liable as a contributory 
infringer.
139
   
In order to establish contributory infringement the party must first establish direct 
infringement.
140
  A panel of Federal Circuit judges has explained that contributory 
infringement is premised on the idea that any defendant who has shown sufficient 
culpability should be held liable, even if he was not a direct infringer and even if 
he did not intend to cause or contribute to infringement.
141
   
In United States Surgical Corporation, it was found that the defendant had 
directly infringed on the plaintiff’s patents.
142
  The court then turned to consider 
whether the defendant was liable for contributory infringement of the plaintiff’s 
                                                        
137
 U.S. Surgical Corp., 701 F. Supp. at 347.  
138
 Am. Med. Sys., Inc., 712 F. Supp. 2d at 905; Sunrise Med. HHG Inc., 95 F. Supp. 2d at 406.   
139
 35 U.S.C. § 271(c) (2006).   
140
 Aro Mfg. Co. v. Convertible Top Replacement Co., 365 U.S. 336, 341 (1961).   
141
 Hewlett-Packard Co. v. Bausch & Lomb, Inc., 909 F.2d 1464, 1469 (Fed. Cir. 1990).  This 
has been further explained that there can be no contributory infringement without knowledge that 
the component was especially adapted for a particular use in a known patent.  Id.   
142
 U.S. Surgical Corp., 701 F. Supp. 314.  United States Surgical Corporation considers the 
510(k) application in their analysis of contributory infringement because they considered the 
510(k) application in their analysis of direct infringement and found that the patents had been 
directly infringed upon.  Id. 
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patents.  The court ruled that the defendant was liable for contributory 
infringement, and again the 510(k) application was considered as evidence in 
considering contributory infringement and was not disallowed.
143
 
3. Infringement Under the Doctrine of Equivalents 
“An accused device that does not literally infringe a claim may still infringe 
under the doctrine of equivalents if each limitation of the claim is met in the 
accused device either literally or equivalently.”
144
  The doctrine of equivalents can 
be applied in cases of patent infringement where each element of a claim is not 
literally infringed, but rather where the difference between the infringing product 
and the claimed limitation are insubstantial to someone who posses an ordinary 
skill in the particular art.
145
  A panel of Federal Circuit judges has cautioned that 
courts may not compare the accused product with the commercial embodiment of 
the patented invention, but it must be compared to the claims that exist 
individually in the patent.
146
   
University of Florida Research Foundation, Inc. v. Orthovita shows how the 
510(k) application materials may have a role in determining infringement by 
equivalents.
147
  In University of Florida Research Foundation, Inc., the plaintiffs 
made a claim for infringement by equivalence, which they planned to prove in 
part by submitting the 510(k) application materials as evidence of infringement by 
equivalence.
148
  The court found that the “FDA submission [is] fatally deficient in 
that [it] compare[s] the accused [infringing product], not to the patent claims, but 
to the commercial embodiment of the patentee’s invention . . . .”
149
  Relying on 
the advice of the Federal Circuit,
150
 the court decided that the 510(k) application 
materials were not suitable as evidence because they did not compare the alleged 
infringed product to the patent claims but rather to the commercial product.
151
   
                                                        
143
 Id. at 350.  
144
 Cybor Corp. v. FAS Techs., Inc., 138 F.3d 1448, 1459 (Fed. Cir. 1998) (citing  Warner-
Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 39–41 (1997); Pennwalt Corp. v. Durand-
Wayland, Inc., 833 F.2d 931, 935 (Fed. Cir. 1987) (en banc)).   
145
 See Warner-Jenkinson Co., Inc. v. Hilton Davis Chem. Co., 520 U.S. 17, 25 (1997) (citing 
Graver Tank & Mfg. Co., Inc., v. Linde Air Products Co., 339 U.S. 605, 609 (1950)).   
146
 Zenith Labs. v. Bristol Myers Squibb Co., 19 F.3d 1418, 1423 (Fed. Cir. 1994).   
147




 Id.     
150
 Under the doctrine of equivalents the parallel between the infringed product and the 
patented invention must be made to the individual patent claims and not to the commercial 
product.  Zenith Labs., 19 F.3d at 1423.   
151
 Univ. of Fla. Research Found., Inc., 1998 WL 34007129, *23.   
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Similar to the case of direct infringement, the court has not ruled whether the 
510(k) application materials should be allowed as evidence of infringement by 
equivalence.  Rather the court decided not to consider the 510(k) application 
materials on the grounds that they compared the infringing device to the available 
commercial product and not the patent claims.  Without a precedential ruling on 
this matter, the same concerns arise in light of considering how a 510(k) 
application may play into patent litigation in the future.  
4. Willful and Deliberate Conduct 
Medical device companies may view what happened in United States Surgical 
Corporation as a warning of how the 510(k) application materials could affect 
their patent infringement litigation.
152
  If a court finds that an infringer acted 
willfully and deliberately they “may increase the damages up to three times the 
amount found or assessed.”
153
  In order to determine whether the infringer acted 
in bad faith the court should consider the elements set out in Bott v. Four Star 
Corp.:  
(1) [W]hether the infringer deliberately copied the ideas or design 
of another; (2) whether the infringer, when he knew of the other’s 
patent protection, investigated the scope of the patent and formed a 
good-faith belief that it was invalid or that it was not infringed, and 
(3) the infringer’s behavior as a party to the litigation.
154
 
In United States Surgical Corporation, the 510(k) application materials were 
considered as evidence in finding direct and contributory infringement.  
Furthermore, all evidence that was submitted for the finding of infringement was 
considered in determining whether there was a finding of willful and deliberate 
conduct.
155
  The court decided that the evidence that was made available 
throughout the course of the trial did show willful and deliberate conduct.  This 
evidence included the 510(k) application materials that had been presented 
throughout the course of the trial.
156
 
While the 510(k) application was not conclusive for the finding of willful and 
deliberate conduct it was considered as a piece of the evidence that eventually 
lead to that finding.  Medical device producers should be aware of this decision 
                                                        
152
 U.S. Surgical Corp., 701 F. Supp. 314.  
153
 35 U.S.C. § 284 (2006); see Beatrice Foods Co. v. New England Printing & Lithographing 
Co., 923 F.2d 1576, 1579 (Fed. Cir. 1991) (finding that enhanced damages may be awarded in 
patent infringement action only as penalty for infringer's increased culpability, namely willful 
infringement or bad faith). 
154
 Bott v. Four Star Corp., 807 F.2d 1567, 1572 (Fed. Cir. 1986).   
155
 U.S. Surgical Corp., 701 F. Supp. at 351.   
156
 Id.   
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when they decide what information should be included in their 510(k) 
applications. 
C. Validity of Resulting Patent 
In CardioVention, Inc. v. Medtronic, Inc., the court ruled that 510(k) materials 
were not admissible at trial to determine validity of patents.
157
  In CardioVention, 
both parties brought motions in limine.  The plaintiff was seeking a declaration 
that the defendant’s patents were invalid or unenforceable, and the defendant 
requested that the court exclude any evidence concerning its listing of the 
plaintiff’s device as a predicate device on its 510(k) application to the FDA.
158
  
The court ruled that the  
Admission of the 510(k) evidence would be misleading and unfairly 
prejudicial to Medtronic.  It would also cause undue delay and a 
waste of time because the parties would litigate the meaning of the 
FDA regulatory system and the difference between that and the 
standards for the claims before the jury.
159
   
The court further stated that the fact that the two inventions in question were 
substantially equivalent, as defined in terms of the FDA, was not the same as if 
they were determined substantially equivalent in the trade secret context.
160
  
Ultimately the court ruled that “[e]ven if the notification is some slight evidence 
of similarity between the [infringing device] and the [patented invention], this 
relevance is substantially outweighed by the danger of confusion, of misleading 
the jury, of undue delay, and of waste of time.”
161
 
In CardioVention, the court decided that the 510(k) application materials were 
not admissible as evidence in determining the invalidity or unenforceability of the 
plaintiff’s patents because the 510(k) application materials would be misleading 
to the jury.
162
  The court based this decision on the majority trend to not allow 
510(k) application materials into patent infringement litigation, as it is widely 
held that the substantial equivalence claim on the 510(k) application is not an 
admission of infringement.     
                                                        
157
 CardioVention, Inc. v. Medtronic, Inc., 483 F. Supp. 2d 830, 840 (D. Minn. 2007).   
158
 Id. at 834.  Plaintiff also asserted claims of breach of contract, misappropriation of trade 
secrets, unfair competition, and intentional interference with prospective economic advantage. Id. 
159
 Id. at 840.   
160
 Id.   
161
 Id. at 841.     
162
 Id. at 840.     
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VI. ANALYSIS OF HOW THE FDA 510(K) PROCESS MAY AFFECT PATENT 
LITIGATION MOVING FORWARD 
Patent law and regulatory law are both important things to consider when 
developing and marketing medical devices.  Medical device manufacturers must 
be able to protect their invention while at the same time getting FDA approval of 
their invention.  Patent law and regulatory law go hand-in-hand in this aspect, as a 
medical device manufacture cannot market his device without first getting FDA 
approval.  At the same time they have to weigh the benefit of patenting a device, 
sometimes before the FDA has approved the device.  Because of the pairing of 
these two areas of law in medical device manufacturing, it is important to 
consider the policy justifications behind both systems.   
The FDA is charged with “promot[ing] the public health by promptly and 
efficiently reviewing clinical research and taking appropriate action on the 
marketing of regulated products in a timely manner.”
163
  Further, the FDA is 
intended to protect the public health by ensuring that there is a reasonable 
assurance of the safety and effectiveness of devices that are intended for human 
use.
164
  In comparison, the widely cited justification for the patent system is to 
promote innovation while at the same time giving the public access to new 
technologies.
165
  This justification for the patent system works because people 
disclose their inventions to the USPTO, which puts the technology in the hands of 
any person wanting to access it, and in turn the patent owner gets the right to 
exclude others from using the invention for a period of twenty years.   
When considering the policy justifications of both systems, it appears as if 
there are some similarities between the two.  One main similarity is that both 
systems are based on the general idea that they are concerned with helping the 
general public.  There is also a similarity in the fact that both have an underlying 
goal of promoting innovation.  The FDA claims to do this by regulating the health 
field, which helps alleviate consumers’ concerns about new drugs and devices.  
The patent system claims to do this by rewarding inventors so they disclose their 
inventions.   
One question that remains unanswered is whether the policy justifications of 
the two systems need to be similar to work efficiently together.  It is arguable that 
they do not have to have the same policy justifications to work well together, but 
that it would make things easier for medical device manufacturers if they did.  
More specifically, it may not matter so much whether the underlying policy goals 
                                                        
163
 21 U.S.C. § 393(b)(1) (2006).   
164
 Id. § 393(b)(2).   
165
 1 R. CARL MOY, MOY‘S WALKER ON PATENTS § 1:26 (4th ed. 2010). 
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are perfectly aligned but whether the two systems have similar goals moving 
forward.   
A. Analysis of How the Changes to the 510(k) System Will Affect Patent 
Validity 
Courts have not agreed whether the 510(k) application should be admissible 
as evidence in determining the validity of patents, as evidenced in the above-cited 
decisions.
166
  Thus, it is important for medical device manufacturers to be aware 
of what information they are releasing in their 510(k) applications.  As evidenced 
by the decision in Mentor H/S, Inc.,
167
 it is also important for medical device 
manufactures to consider what information they disclose to the USPTO, as the 
510(k) application materials can be used in considering whether inequitable 
conduct has taken place.   
When considering the changes that are being made to the 510(k) process, it is 
important to think about how this may affect patent validity questions.  The 
proposed change to switch the 510(k) application to be based upon an assurance 
case framework means that manufacturers will need to state detailed claims about 
the effectiveness and safety of their device.
168
  It also means that incomplete 
510(k) applications will not be looked at.  The result of this change will be that 
510(k) applications will need to include a more detailed description of a device 
and its intended use, which means there is potentially more information available 
that can be used in evaluating patent validity.  This information may be 
admissible if the patent application is filed more than a year after the 510(k) 
application is submitted (concerning novelty) or if there is a claim of infringement 
(as a party defending against an infringement case could use a more detailed 
analysis to prove that the patent was anticipated or obvious and thus invalid).   
There are also changes proposed that would require a medical device 
manufacturer to submit more specific information with their 510(k) application.
169
  
These changes include: providing scientific evidence, providing photographs and 
schematics, and providing manufacturing process information.  This additional 
information that may be required may also be used to point to the fact that a 
claimed invention is anticipated or obvious. 
The major concern that arises when comparing the changes to the 510(k) 
system with the patent process is related to the publicly available database.
170
  
                                                        
166
 See supra Part IV.   
167
 Mentor H/S, Inc. v. Med. Device Alliance Inc., 244 F.3d 1365 (Fed. Cir. 2001).   
168
 See supra Part III.B.1.   
169
 See supra Part III.B.2–4.     
170
 See supra Part III.B.7.   
25
Alm: The Evolving 510(k) System and its Effect on Patent Litigation
Published by Mitchell Hamline Open Access, 2012
[3:160 2012] THE EVOLVING 510(K) SYSTEM AND  185 
ITS EFFECT ON PATENT LITIGATION 
Under the current system only the 510(k) summary is made public when a device 
is approved through the 510(k) process.
171
  The proposed change to the 510(k) 
system would include photographs, schematics, or drawings published with every 
510(k) application that has been approved, as well as information regarding how 
the current device is similar to the claimed predicate device.
172
  The concern that 
arises under this situation in relation to patent validity is whether submitting the 
510(k) application would be considered a disclosure of the invention.  While one 
has a year window in which to file their patent application after the disclosure of 
their invention,
173
 publishing a more comprehensive 510(k) summary on the FDA 
website could lead to trouble for those who fail to file their patent application in a 
timely fashion.  There is currently no binding precedential rule that states whether 
or not the 510(k) application can be used as a means of showing that the device 
was anticipated or obvious.
174
  Publishing more detailed 510(k) applications in a 
publically searchable database may prove to be problematic until it is determined 
how the 510(k) application may play into determining the validity of a patent.   
B. Analysis of How the Changes to the 510(k) System May Affect Patent 
Litigation 
In light of the changes that are being made to the 510(k) system, medical 
device companies will also need to be especially aware of how the information in 
their 510(k) application may play into patent litigation cases.   
The concern that arises out of the switch to an assurance case framework
175
 is 
that because medical device manufacturers will be required to give a more 
detailed description of how their device is similar to the predicate device they are 
claiming, it may lead to more findings of patent infringement.  Courts have 
typically held that the 510(k) application materials are not admissible as evidence 
in patent litigation cases because the FDA’s definition of a ‘substantial 
equivalent’ is different than the definition of a ‘substantial equivalent’ in a patent 
context.
176
  But if a manufacturer is required to provide a detailed claim of how 
their device is similar to the substantial equivalent, the later courts may follow the 
                                                        
171
 21 C.F.R. § 807.95(d) (2010).  The 510(k) summary needs to include enough information to 
provide a basis for finding a claim of substantial equivalence.  This includes, among other things, 
identification of the claimed substantially equivalent device, description of the current device, a 
description of the devices intended use, and a summary of the technological characteristics of the 
current device compared to the claimed substantial equivalent.  Id.  § 807.92(a).   
172
 See supra Part III.B.7; see also 510(k) and Science Report Recommendations, supra note 
25, at 20.   
173
 35 U.S.C. § 102(b) (2006).   
174
 See cases cited supra Part IV.   
175
 See supra Part III.B.1.  
176
 See supra Part V.B; see, e.g., Am. Med. Sys., Inc., 712 F. Supp. 2d at 905 (D. Minn. 2010) 
(citing CardioVention, Inc. v. Medtronic, Inc., 483 F. Supp. 2d 830, 840 (D. Minn. 2007)).   
26
Cybaris®, Vol. 3, Iss. 2 [2012], Art. 2
http://open.mitchellhamline.edu/cybaris/vol3/iss2/2
[3:160 2012] CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW 186 
 
decision in United States Surgical Corporation and allow the 510(k) application 
materials into cases considering patent infringement.
177
 
The changes that will require more information to be given in the 510(k) 
application (providing scientific evidence, providing photographs and schematics, 
and providing manufacturing process information)
178
 may also have the same 
effect on patent litigation.  That is, with more detailed information being disclosed 
in the 510(k) application, more courts may be likely to consider the 510(k) 
application materials in patent litigation cases.   
There is also a concern that having to provide more detailed information will 
cause problems with people infringing devices claimed on 510(k) applications 
that may be published in the 510(k) database.
179
  Providing photographs or 
schematics to the general public, along with more detailed 510(k) summaries, 
may cause issues with reverse engineering.  While the FDA claims confidential 
information will still be kept confidential,
180
 there is a concern that the increase in 
the amount of information that is given to the FDA through the 510(k) process 
may lead to more problems.  More detailed information about the intended use of 
a device and more detailed information about how the current device is 
substantially equivalent to the claimed predicate device, paired with photographs 
or schematics, may lead to more problems than predicted. 
Considering the formation of a new class of devices, Class IIb devices, the 
same concerns arise.
181
  Class IIb device 510(k) applications are going to be 
required to have more detailed information submitted, including the three changes 
listed above.
182
  Devices that are classified as Class IIb devices are going to have 
larger hurdles to overcome in order to get their 510(k) approval, which in turn 
means a lot more information will be released.  This raises a lot of concern about 
how this information may lead to others reverse engineering the devices and/or 
how the information released under the 510(k) application may play into future 
patent litigation.   
Another concern arises out of the limited use (or potential elimination) of 
using multiple predicates on a 510(k) application.
183
  If a party is held to only 
claim substantial equivalence to one device there may be a greater link drawn 
between the technological characteristics of the current device and the claimed 
                                                        
177
 See U.S. Surgical Corp., 701 F. Supp. at 347.   
178
 See supra Part III.B.2-4.   
179
 See supra Part III.B.7.   
180
 See 510(k) and Science Report Recommendations, supra note 25, at 20.   
181
 See supra Part III.B.6.   
182
 510(k) and Science Report Recommendations, supra note 25, at 17–18.   
183
 See supra Part III.B.5.   
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predicate device.  Again, there may be a situation where the courts follow the idea 
in United States Surgical Corporation and allow these materials to be submitted 
in patent infringement cases due to the higher level of information being disclosed 
and the more direct link being made between the two devices.
184
 
As the 510(k) system gets more rigorous there is uncertainty about how it will 
affect the area of patent law.  Since the Eli Lilly decision, it has been widely held 
that the substantial equivalence claimed in the 510(k) application cannot be held 
as an admission of direct infringement.
185
  But there is currently no binding ruling 
that is widely held as precedent on how 510(k) application materials can play into 
other aspects of patent litigation.  And until there is a binding ruling or statutory 
language spelling it out, medical device manufacturers need to be especially 
aware of what information they are releasing in their 510(k) applications to the 
FDA.    
VII. CONCLUSION:  HOW INVENTORS MAY PROTECT THEMSELVES UNDER THE 
NEW 510(K) STRUCTURE 
Medical device manufacturers would be wise to be very careful with the 
information they disclose in their 510(k) applications moving forward.  They have 
two main options moving forward.  The first will be to supply all information the 
FDA asks for in great detail to ensure that their 510(k) application is approved in 
a timely manner.  If this first approach is taken it will be important for medical 
device manufactures to be aware of how the information they are releasing may 
be used in determining the validity of their patent application or how the 
information may play into future patent infringement claims.  The second option 
is to release as little information as necessary under the new changes.  The danger 
in choosing this option is that the CDRH may decide it is not sufficient and the 
medical device manufacturers may be asked for additional materials, which could 
slow down the approval of their device for marketing.   
While neither choice is a good option, medical device companies may be 
better protected by trying to release only the information that is necessary, taking 
the risk that it may slow down the approval of their device for market.  This 
approach is the best strategy for medical device manufacturers until there is 
statutory language or a binding ruling defining exactly how 510(k) application 
materials may play into patent litigation.   
   
                                                        
184
 See U.S. Surgical Corp., 701 F. Supp. at 347.   
185
 See Eli Lilly & Co., 496 U.S. at 665–70 (1990).  See also, e.g., Am. Med. Sys., Inc. v. Laser 
Peripherals, LLC, 712 F. Supp. 2d 885, 905 (D. Minn. 2010); Sunrise Med. HHG, Inc. v. Airsep 
Corp., 95 F. Supp. 2d 348, 406 (W.D. Pa. 2000).   
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